ENLV
Income statement / Annual
Last year (2025), Enlivex Therapeutics Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Enlivex Therapeutics Ltd's net income was $1.24 B.
See Enlivex Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.28 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$332.00 K
|
$545.00 K
|
$835.00 K
|
$777.00 K
|
$546.00 K
|
$286.00 K
|
$297.00 K
|
$121.00 K
|
$12.00 K
|
$25.00 K
|
| Gross Profit |
-$332.00 K
|
-$545.00 K
|
-$835.00 K
|
-$777.00 K
|
-$546.00 K
|
-$286.00 K
|
-$297.00 K
|
-$121.00 K
|
-$12.00 K
|
-$25.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
-0.13
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$8.92 M
|
$10.13 M
|
$19.24 M
|
$18.69 M
|
$12.88 M
|
$6.09 M
|
$5.72 M
|
$4.13 M
|
$2.52 M
|
$8.88 M
|
| General & Administrative Expenses |
$5.69 M
|
$4.91 M
|
$6.14 M
|
$6.70 M
|
$6.24 M
|
$3.60 M
|
$2.75 M
|
$937.00 K
|
$2.96 M
|
$6.99 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$479.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.69 M
|
$4.91 M
|
$6.14 M
|
$6.70 M
|
$6.24 M
|
$3.60 M
|
$2.75 M
|
$1.04 M
|
$3.44 M
|
$6.99 M
|
| Other Expenses |
$61.00 K
|
-$48.00 K
|
$4.02 M
|
$402.00 K
|
$167.00 K
|
$97.00 K
|
$145.00 K
|
$0.00
|
-$117.00 K
|
-$1.95 M
|
| Operating Expenses |
$14.67 M
|
$14.99 M
|
$29.40 M
|
$25.80 M
|
$19.29 M
|
$9.79 M
|
$8.62 M
|
$5.18 M
|
$5.84 M
|
$13.92 M
|
| Cost And Expenses |
$15.00 M
|
$15.54 M
|
$29.40 M
|
$25.80 M
|
$19.29 M
|
$8.57 M
|
$8.62 M
|
$5.30 M
|
$5.85 M
|
$13.95 M
|
| Interest Income |
$792.00 K
|
$1.07 M
|
$1.57 M
|
$835.00 K
|
$120.00 K
|
$225.00 K
|
$238.00 K
|
$138.00 K
|
$39.00 K
|
$90.00 K
|
| Interest Expense |
$13.00 K
|
$13.00 K
|
$14.00 K
|
$5.26 M
|
$328.00 K
|
$6.00 K
|
$7.00 K
|
$3.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$332.00 K
|
$545.00 K
|
$835.00 K
|
$777.00 K
|
$546.00 K
|
$286.00 K
|
$206.00 K
|
$121.00 K
|
$12.00 K
|
$25.00 K
|
| EBITDA |
-$14.67 M |
-$14.47 M |
-$28.22 M |
-$25.02 M |
-$18.74 M |
-$9.50 M |
-$8.41 M |
-$5.18 M |
-$5.91 M |
-$15.78 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-4.17
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-4.3
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.63 B
|
$522.00 K
|
$327.00 K
|
-$5.26 M
|
$4.82 M
|
-$2.04 M
|
-$765.00 K
|
$1.06 M
|
-$67.00 K
|
-$1.86 M
|
| Income Before Tax |
$1.62 B
|
-$15.01 M
|
-$29.07 M
|
-$31.06 M
|
-$14.47 M
|
-$11.82 M
|
-$9.38 M
|
-$4.24 M
|
-$5.92 M
|
-$15.81 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-5.19
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$382.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.00 K
|
$216.00 K
|
| Net Income |
$1.24 B
|
-$15.01 M
|
-$29.07 M
|
-$31.06 M
|
-$14.47 M
|
-$11.82 M
|
-$9.38 M
|
-$4.24 M
|
-$5.95 M
|
-$16.02 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-5.19
|
0
|
0
|
0
|
0
|
| EPS |
405.6 |
-10.95 |
-23.4 |
-34.65 |
-8.1 |
-15.75 |
-17.55 |
-159.45 |
-215.25 |
-604.35 |
| EPS Diluted |
382.2 |
-10.95 |
-23.4 |
-34.65 |
-8.1 |
-15.75 |
-17.55 |
-159.45 |
-208.2 |
-604.35 |
| Weighted Average Shares Out |
$3.05 M
|
$1.37 M
|
$1.24 M
|
$1.23 M
|
$1.19 M
|
$877.95 K
|
$576.63 K
|
$30.74 K
|
$27.61 K
|
$26.51 K
|
| Weighted Average Shares Out Diluted |
$3.23 M
|
$1.37 M
|
$1.24 M
|
$1.23 M
|
$1.19 M
|
$877.95 K
|
$576.63 K
|
$30.74 K
|
$28.55 K
|
$26.51 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
